Excelra, a top provider of digital and data-driven life science solutions, has acquired BISC Global, a bioinformatics and data analytics consulting firm with locations in the US and Europe. With expertise in omics and next-generation sequencing data processing, machine learning, and artificial intelligence, the acquisition creates an international powerhouse in consulting-led bioinformatics.
The best pharmaceutical and biotechnology firms in the world rely on Excelra for data, analysis, and R&D technology services. To speed up the discovery and development of new drugs, its interdisciplinary teams of biocurators, bioinformaticians, data scientists, and engineers supply harmonised data, optimised analysis pipelines, and cutting-edge applications.
A platform and service provider lead by consultancy, BISC Global specialises in bioinformatics, biostatistics, artificial intelligence, and machine learning. It offers cloud computing, data visualisation, data analysis, and pipeline development services. It also offers next-generation platforms like ImmunoRaptor, an analysis platform that makes it simple for researchers to manage and analyse immune repertoire sequencing data, and the Online Pipeline Platform (OP2), which supports streamlined analysis of bulk RNA-seq, single-cell RNA-seq, somatic variant calling, and germline variant calling data.
The management of BISC Global is certain that the acquisition would increase bioinformatics innovation and benefit clients of both companies. "We are excited about the acquisition by Excelra and are confident that the synergies between our two organisations will enable our consultants to provide best-in-class bioinformatics services to the life science industry," stated Maarten Braspenning, CEO of BISC Global.
Excelra CEO Anandbir Singh Brar said, "The acquisition of BISC Global is a strategic move that enhances our capabilities and expands our reach in the bioinformatics field. The combined entity will be amongst the industry leaders in bioinformatics platforms and services, and will have a major positive impact on the future of bioinformatics and the life science industry."
The merger establishes a revolutionary bioinformatics powerhouse dedicated to fostering innovation at the nexus of science and technology.
